MODULATION OF MUCOSAL RESPONSES TO HIV GP160 BY IL-12

IL-12 对 HIV GP160 的粘膜反应的调节

• 批准号: 2657346
• 负责人: MARK A MILLER
• 金额: $ 3.84万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 1998-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2657346
• 关键词: HIV envelope protein gp160; active immunization; enzyme linked immunosorbent assay; gene therapy; immunomodulators; in situ hybridization; interleukin 12; laboratory mouse; microorganism immunology; mucosal immunity; polymerase chain reaction; recombinant proteins

DESCRIPTION: The applicant will thoroughly characterize the murine mucosal and systemic responses (cellular and humoral) generated by immunization with HIV envelope protein, and the effectiveness of IL-12 as an adjuvant for the production of immunity at mucosal surfaces will also be examined. In Aim 1, the ability to enhance mucosal immunity by co-administering recombinant IL-12 with HIV gp160 via the oral and intranasal route will be assessed. In Aim 2, DNA IL-12 will be delivered either mucosally or remotely by IM or gene gun, and similar characterizations of immune responses will be performed. In Aim 3, experiments will examine the potential dysregulation of mucosal immune responses by immunization with rgp160 in combination with IL-12 protein or the plasmid DNA-IL-12.

描述：申请方将彻底表征小鼠粘膜 免疫接种产生的全身反应（细胞和体液） HIV包膜蛋白，以及IL-12作为HIV免疫佐剂的有效性。 还将检查粘膜表面的免疫产生。 在目标1中， 通过共施用重组体增强粘膜免疫能力 将评估IL-12与HIV gp 160通过口服和鼻内途径的作用。 在 目的2，DNA IL-12将通过IM或肌内注射经粘膜或远程递送。 基因枪，以及类似的免疫反应特征， 执行。 在目标3中，实验将检查潜在的失调， 粘膜免疫应答的影响 IL-12蛋白或质粒DNA-IL-12。